CGBio, specializing in bio-regenerative medicine (CEO Hyun Seung Yu), announced on the 21st that they hosted the Consensus Symposium for Clinical Application and Commemoration of the Release of Giselleligne Signature 2 (Giselleligne Max in Chinese), their hyaluronic acid (HA) filler officially released in China’s market, at Ripple Art Space in Shanghai, China.
In October 2022, CGBio acquired the permit for Giselleligne Signature 2 from the National Medical Products Administration (NMPA), and in March this year, signed a contract worth approximately KRW70 billion for supply to China over a period of three years. The recent event was the first official launching event after the export contract. It was organized to introduce its second premium filler following Giselleligne Universal, in an effort to strengthen its market dominance in China’s rapidly growing cosmetic surgery market.
The symposium was jointly held by Shanghai Bijeong Trading LLC, the local distribution partner for Giselleligne Signature 2 in China. It was attended by around 150 cosmetic surgery specialists and 10 key opinion leaders. The event began with congratulatory messages from CGBio CEO Hyun Seung Yu and Shanghai Bijeong Trading LLC, followed by the introduction of Giselleligne Signature 2, a presentation of clinical findings for Giselleligne Signature 2, and a discussion on various clinical application methods for Giselleligne.
Giselleligne is a premium HA filler developed by CGBio. It combines a biphasic filler with high elasticity to provide distinct volume enhancement and a gel-type monophasic filler with good viscosity to achieve natural-looking aesthetic results. This combination is formulated based on the principles of rotation and revolution at a specific ratio. The result is a remarkable enhancement in volume and a seamless, natural appearance, especially along the boundaries where the filler is injected.
In particular, Giselleligne Signature 2, one of the three products in the Giselleligne line (Giselleligne Signature 1, Giselleligne Universal, Giselleligne Signature 2), is specifically designed for injection into areas with relatively thick skin such as the chin and the bridge of the nose. It is formulated with lidocaine, a local anesthetic agent, to help minimize discomfort during the filler procedure.
Dr. Jeong Jae-yoon, who presented the clinical findings for Giselleligne Signature 2 said, “Through property comparison, HA dissolution test, and modification degree (MOD) value analysis, it has been verified that Giselleligne Signature 2 offers distinct advantages over other products and demonstrates safety across all indicators”, adding, “The filler’s retention rate was especially high. When injected into the nose and chin area, it provided stable results and achieved a defined look even with a small amount”.
With the official launch, CGBio is planning to enhance the training of local medical specialists through Visiting Clinician Program (VCP), where Chinese medical specialists are invited to observe the filler procedure process conducted by Korean medical specialists, and CADAVER Workshop, where participants can acquire surgical skills through practical training, and carry out various marketing campaigns to facilitate the exchange in cosmetic surgery between South Korea and China.
CEO Hyun Seung Yu said, “Giselleligne is the world’s first multi-layered phasic filler with a two-in-one structure, designed to achieve a distinct yet natural volume and contour. It has already proven itself in the Korean market, giving it a strong competitive edge in the Chinese market”, adding, “We will continue to pursue higher quality and provide better products”.
According to a report published by KITA this year, the medical beauty market in China was around RMB 264.3 billion (equivalent to approximately KRW5.18 billion) in 2022, which is nearly three times the value recorded in 2016 (RMB 84.1 billion), and is projected to reach RMB 311.5 billion (equivalent to KRW61.1 trillion) in 2023.
▲ CGBio launches HA filler Giselleligne Signature 2 in China Taking the first step into the market following the signing of a KRW70 billion supply contract
▲ CGBio launches HA filler Giselleligne Signature 2 in China Taking the first step into the market following the signing of a KRW70 billion supply contract
▲ CGBio launches HA filler Giselleligne Signature 2 in China Taking the first step into the market following the signing of a KRW70 billion supply contract
